July 8, 2010
On July 1, 2010, Pharmacosmos and Vitaline Pharmaceuticals
formally agreed to enhance their collaboration by merging
Pharmacosmos and Vitaline Pharmaceuticals. Pharmacosmos' new,
fully-owned UK subsidiary will be named Pharmacosmos UK and Mr.
Colin Boots is appointed General Manager.
"We are truly delighted to announce this important step
forward for Pharmacosmos. Vitaline Pharmaceuticals has always been
our preferred partner in the UK, because we feel a strong, shared
aspiration for providing patients and healthcare professionals with
quality treatment for iron deficiency anaemia," says Lars
Christensen, M.D., President and CEO of Pharmacosmos: "We
believe strongly in Colin Boots and his team's commitment to
advance treatment of iron deficiency anaemia. By establishing
Pharmacosmos UK we are eager to continue and improve our service
offering to healthcare professionals involved in IV iron
Colin Boots, General Manager of Vitaline Pharmaceuticals, says,
"The close and strong relationship we have shared with
Pharmacosmos for more than 10 years makes this decision a preferred
next step for Vitaline. Pharmacosmos is a perfect fit for us and we
believe that joining the Pharmacosmos family will help us further
improve treatment options for patients with iron deficiency anaemia
A key task for Pharmacosmos UK will be the launch of
Monofer® (iron isomaltoside 1000) in July, a new IV iron
product for the treatment of iron deficiency anaemia1.
Monofer® is developed by Pharmacosmos and offers the possibility of
full iron repletion in one, rapid visit1.
Today, Monofer® is approved in 16 countries, including: Belgium,
Bulgaria, Denmark, Finland, Estonia, Iceland, Ireland, Latvia,
Lithuania, Netherlands, Norway, Poland, Portugal, Romania, Sweden,
and the United Kingdom.
Contact for further information
Lars Christensen, M.D.
President and CEO
T: +45 5948 5959
1) Monofer® Core Summary of Product
© 2010 Pharmacosmos A/S. Monofer® is a
registered trademark of Pharmacosmos A/S.
About Pharmacosmos A/S
Headquartered in Denmark, Pharmacosmos is a family-owned,
international healthcare company with more than 50 years of
innovation and leadership in iron- and carbohydrate-based
treatments and solutions for human and animal use.
A research-based company, its ongoing R&D programme focuses
on improving the lives of patients with iron deficiency with or
without anaemia. More than 1 billion people live with iron
deficiency anaemia and it is the leading cause of death for an
estimated 180,000 people every year. This makes it one of the
largest global health challenges of our time.
Pharmacosmos has subsidiaries in the Nordics, the UK and the US
and its products are marketed in more than 80 countries across the
world. Its manufacturing facilities are approved, among others, by
the Danish Medicines Agency and the US FDA.